These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22743296)

  • 1. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.
    Gautschi O; Pauli C; Strobel K; Hirschmann A; Printzen G; Aebi S; Diebold J
    J Thorac Oncol; 2012 Oct; 7(10):e23-4. PubMed ID: 22743296
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.
    Myall NJ; Neal JW; Cho-Phan CD; Zhou LY; Stehr H; Zhou L; Diehn M; Wakelee HA
    Clin Lung Cancer; 2016 Mar; 17(2):e17-21. PubMed ID: 26776917
    [No Abstract]   [Full Text] [Related]  

  • 3. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.
    Gautschi O; Peters S; Zoete V; Aebersold-Keller F; Strobel K; Schwizer B; Hirschmann A; Michielin O; Diebold J
    Lung Cancer; 2013 Nov; 82(2):365-7. PubMed ID: 24035431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
    Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
    Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
    Schmid S; Siano M; Joerger M; Rodriguez R; Müller J; Früh M
    Lung Cancer; 2015 Jan; 87(1):85-7. PubMed ID: 25466451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.
    Peters S; Michielin O; Zimmermann S
    J Clin Oncol; 2013 Jul; 31(20):e341-4. PubMed ID: 23733758
    [No Abstract]   [Full Text] [Related]  

  • 7. BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib.
    El Karak F; Assi T; Kourie HR; El Rassy E; Chebib R; Ghor M; Tabchi S
    Int J Clin Exp Pathol; 2015; 8(3):3294-8. PubMed ID: 26045855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
    Starz H; Gutschi M; Welzel J; Haas C
    J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
    [No Abstract]   [Full Text] [Related]  

  • 9. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.
    Charles J; Beani JC; Fiandrino G; Busser B
    J Am Acad Dermatol; 2014 Sep; 71(3):e97-9. PubMed ID: 25128147
    [No Abstract]   [Full Text] [Related]  

  • 10. Granuloma Annulare Secondary to Vemurafenib Therapy for Lung Adenocarcinoma.
    Jenkinson HA; Siroy AE; Choksi A
    J Drugs Dermatol; 2017 Oct; 16(10):1050-1052. PubMed ID: 29036262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.
    Koers K; Francken AB; Haanen JB; Woerdeman LA; van der Hage JA
    J Clin Oncol; 2013 Jun; 31(16):e251-3. PubMed ID: 23569313
    [No Abstract]   [Full Text] [Related]  

  • 12. Sustained Response to Vemurafenib in a BRAF
    Prager GW; Koperek O; Mayerhoefer ME; Muellauer L; Wrba F; Niederle B; Zielinski CC; Raderer M
    Thyroid; 2016 Oct; 26(10):1515-1516. PubMed ID: 27532222
    [No Abstract]   [Full Text] [Related]  

  • 13. Overcoming resistance in a
    Schmid T; Buess M
    Curr Oncol; 2018 Jun; 25(3):e217-e219. PubMed ID: 29962848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vemurafenib.
    Garbe C; Abusaif S; Eigentler TK
    Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib.
    Idbaih A; Mokhtari K; Emile JF; Galanaud D; Belaid H; de Bernard S; Benameur N; Barlog VC; Psimaras D; Donadieu J; Carpentier C; Martin-Duverneuil N; Haroche J; Feuvret L; Zahr N; Delattre JY; Hoang-Xuan K
    Neurology; 2014 Oct; 83(16):1478-80. PubMed ID: 25209580
    [No Abstract]   [Full Text] [Related]  

  • 16. Pilomyxoid astrocytoma treated successfully with vemurafenib.
    Skrypek M; Foreman N; Guillaume D; Moertel C
    Pediatr Blood Cancer; 2014 Nov; 61(11):2099-100. PubMed ID: 24821190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 19. The histopathology of BRAF-V600E-mutated lung adenocarcinoma.
    Yousem SA; Nikiforova M; Nikiforov Y
    Am J Surg Pathol; 2008 Sep; 32(9):1317-21. PubMed ID: 18636014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.